This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cronos (CRON) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top- and bottom-line numbers, along with its pipeline progress, when it reports Q4 results.
Implied Volatility Surging for Adamas Pharmaceuticals (ADMS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Adamas Pharmaceuticals (ADMS) stock based on the movements in the options market lately.
Adamas Pharmaceuticals (ADMS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of -10.00% and -2.97%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
What's in the Offing for Humana's (HUM) Earnings in Q3?
by Zacks Equity Research
Humana's (HUM) third-quarter results are likely to reflect rise in expenses and a negative impact from seasonality on its bottom line.
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Adamas Pharmaceuticals (ADMS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
Better-than-expected performance at Technology & Equipment and growth in emerging markets are likely to aid DENTSPLY SIRONA (XRAY) in Q2 earnings.
Top Ranked Momentum Stocks to Buy for July 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 8th.
Bausch Gains 38.9% YTD on Product Launches & Debt Reduction
by Zacks Equity Research
Bausch (BHC) is currently focusing on widening its ophthalmology and dermatology portfolio.
Price Stabilization Leads to Generic Drugs Industry's Recovery
by Indrajit Bandyopadhyay
Stabilizing prices of generic drugs is leading to a recovery in revenues of industry participants. New launches are also providing a boost. However, competition remains stiff.
Will Adamas Pharmaceuticals Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Adamas Pharmaceuticals.
Bausch Health (BHC) Catches Eye: Stock Jumps 6.2%
by Zacks Equity Research
Bausch Health (BHC) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Allergan (AGN) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Allergan (AGN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
What Makes Adamas (ADMS) a New Buy Stock
by Zacks Equity Research
Adamas (ADMS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Adamas (ADMS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Adamas (ADMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Adamas Pharmaceuticals (ADMS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of 4.42% and -8.75%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Adamas Pharmaceuticals (ADMS) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Adamas (ADMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.
Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
by Zacks Equity Research
Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.
AptarGroup (ATR) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
AptarGroup (ATR) fourth-quarter results will benefit from successful product roll outs and focus on improving operations despite input cost inflation and customer plant shutdowns.
Milacron (MCRN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Milacron's (MCRN) cost-reduction initiatives are expected to yield around $35 million of annual run-rate cost savings in the fourth quarter.
Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?
by Zacks Equity Research
Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adamas (ADMS) delivered earnings and revenue surprises of 10.64% and 56.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?